Jaguar Health, Inc. (NASDAQ:JAGX) | Finanzwire

Basculer en Français

9472	Companies
185369	Keywords
117719	Articles
99261	Press releases

Home
Companies
Jaguar Health, Inc.

BRIEF

published on 12/02/2025 at 15:05, 2 days 14 hours ago

Jaguar Health Seeks EMA Approval for Canalevia to Treat Dog Diarrhea

Jaguar Health European Medicines Agency Dog Diarrhea Canalevia Approval Non-antibiotic Treatment
PRESS RELEASE

published on 12/02/2025 at 15:00, 2 days 15 hours ago

Jaguar Health Makes Submission to EMA Regarding EU Approval Pathway for Canalevia for General Diarrhea in Dogs Based on Data from Completed Study
Jaguar Health, Inc. requests advice from EMA on EU approval pathway for Canalevia® in treating general diarrhea in dogs. Novel non-antibiotic approach targets a significant market gap

Jaguar Health Dogs EMA Canalevia General Diarrhea
BRIEF

published on 11/24/2025 at 15:05, 10 days 14 hours ago

Jaguar Health Strengthens IP with New Patent for Crofelemer in Intestinal Disorders

Crofelemer Patent Clinical Trials Jaguar Health Intestinal Disorders
PRESS RELEASE

published on 11/24/2025 at 15:00, 10 days 15 hours ago

Jaguar Health Secures New Patent for Crofelemer in Short Bowel Syndrome, Strengthening Global IP Position Ahead of Additional Clinical Milestones
Jaguar Health, Inc. secures new patent expanding international IP for crofelemer in pediatric intestinal failure disorders, highlighting reductions in parenteral support. Supporting business development plans

Crofelemer Business Development Jaguar Health Inc. Pediatric Intestinal Failure New Patent
BRIEF

published on 11/20/2025 at 15:05, 14 days 14 hours ago

Crofelemer Shows Potential for Expedited Approval in Treating MVID

Crofelemer Microvillus Inclusion Disease FDA Approval Clinical Trials Jaguar Health
PRESS RELEASE

published on 11/20/2025 at 15:00, 14 days 15 hours ago

In Support of Possible Expedited Approval Pathway for Crofelemer for Treatment of Microvillus Inclusion Disease (MVID), Jaguar Health Submits Amended Protocol to FDA for Ongoing Placebo-Controlled Clinical Trial
Jaguar Health submits amended protocol to FDA for crofelemer in pediatric MVID patients to potentially extend lives and reduce parenteral support by up to 37%

FDA Crofelemer Jaguar Health Pediatric Patients MVID
BRIEF

published on 11/17/2025 at 14:05, 17 days 15 hours ago

Jaguar Health Reports Modest Revenue Increase in Q3 2025 Financials

Crofelemer Jaguar Health Net Revenue Q3 Financials MVID Treatment
PRESS RELEASE

published on 11/17/2025 at 14:00, 17 days 16 hours ago

Jaguar Health Reports Third Quarter 2025 Financials: Net Q3 2025 Revenue Up Approximately 4% Versus Net Q2 2025 Revenue
Jaguar Health, Inc. reports proof-of-concept trial shows crofelemer potential for MVID patients, financial results revealed, FDA meeting outcome, and upcoming investor webcast

Financial Results Crofelemer Investor Webcast Jaguar Health Inc. MVID
BRIEF

published on 11/14/2025 at 15:05, 20 days 14 hours ago

Jaguar Health to Host Investor Webcast on November 17, 2025

Financial Report Investor Webcast Jaguar Health Magdalena Biosciences Gastrointestinal Medicines
PRESS RELEASE

published on 11/14/2025 at 15:00, 20 days 15 hours ago

Jaguar Health to Hold Investor Webcast Monday, November 17 at 8:30 AM Eastern Regarding Q3 2025 Financials & Corporate Updates
Jaguar Health, Inc. (NASDAQ:JAGX) to file Earnings Report on Form 10-Q for quarter ended September 30, 2025. Investor webcast on November 17, 2025 at 8:30 a.m. Eastern to review financials and provide corporate updates

Earnings Report Investor Webcast Jaguar Health Form 10-Q NASDAQ:JAGX

Accesswire

Published on 12/05/2025 at 02:35, 3 hours 28 minutes ago

Future Fuels Initates Drill Permitting at Hornby; Marketing Update
Published on 12/05/2025 at 02:30, 3 hours 33 minutes ago

Klondike Gold Announces AGM Results
Published on 12/05/2025 at 01:00, 5 hours 3 minutes ago

BEACN Closes First Tranche of Non-Brokered Private Placement
Published on 12/04/2025 at 23:05, 6 hours 58 minutes ago

BlackBerry to Announce Third Quarter Fiscal Year 2026 Results on December 18, 2025
Published on 12/04/2025 at 23:00, 7 hours 3 minutes ago

NXT Energy Solutions Completes Data Acquisition for SFD Survey

View all ACCESSWIRE

EQS Group

Published on 12/05/2025 at 03:30, 2 hours 32 minutes ago

CGTN: What makes cooperation between China and France a two-way success
Published on 12/04/2025 at 23:50, 6 hours 12 minutes ago

EQS-Adhoc: Dexus Finance Pty Limited: Dexus prices A$500 million of subordinated notes
Published on 12/04/2025 at 20:25, 9 hours 37 minutes ago

Newmark Appoints Globally Recognized Real Estate Executive Peter Trollope to Lead Occupier Solutions
Published on 12/04/2025 at 20:15, 9 hours 47 minutes ago

Galimedix Therapeutics presents compelling Phase 1 study results showing excellent safety and pharmacokinetics with oral small molecule GAL-101 at CTAD 2025
Published on 12/04/2025 at 19:10, 10 hours 52 minutes ago

SCHOTT Pharma’s preliminary results for fiscal year 2025; outlook for FY 2026 and update of mid-term guidance

Les Echos

Published on 12/04/2025 at 18:00, 12 hours 3 minutes ago

Information concerning the total number of voting rights and shares in the share capital as of November 28, 2025
Published on 12/04/2025 at 17:45, 12 hours 18 minutes ago

MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
Published on 12/04/2025 at 17:44, 12 hours 18 minutes ago

Net profit attributable to owners of the parent up by 63% to €122 million, driven by business resilience and the improvement in Elior's contribution
Published on 12/04/2025 at 07:01, 23 hours 2 minutes ago

bioMérieux launches leading endocrinology testing offer dedicated to enhancing equine health
Published on 12/03/2025 at 18:00, 1 day 12 hours ago

Declaration of voting rights at the end of November 2025

View all LES ECHOS COMFI WIRE